id,agency_id,docket_id,title,document_type,subtype,posted_date,posted_year,posted_month,comment_start_date,comment_end_date,last_modified,fr_doc_num,open_for_comment,withdrawn,object_id
FDA-2011-E-0156-0007,FDA,FDA-2011-E-0156,Letter to U. S. Patent and Trademark Office,Other,Letter(s),2012-12-27T05:00:00Z,2012,12,2012-12-27T05:00:00Z,,2024-03-13T11:35:54Z,,0,0,090000648119c23a
FDA-2011-E-0156-0006,FDA,FDA-2011-E-0156,Determination of Regulatory Review Period for Purposes of Patent Extension: HALAVEN,Notice,General Notice,2012-05-03T04:00:00Z,2012,5,2012-05-03T04:00:00Z,,2012-05-03T15:55:21Z,2012-10716,0,0,090000648100432d
FDA-2011-E-0156-0005,FDA,FDA-2011-E-0156,Letter to U. S. Patent and Trademark Office,Other,Letter(s),2012-04-18T04:00:00Z,2012,4,2012-04-18T04:00:00Z,,2024-03-13T11:35:32Z,,0,0,0900006480ff32b7
FDA-2011-E-0156-0004,FDA,FDA-2011-E-0156,Letter to U. S. Patent & Trademark Office,Other,Letter(s),2012-01-10T05:00:00Z,2012,1,2012-01-10T05:00:00Z,,2024-03-13T12:29:58Z,,0,0,0900006480f91f11